KAS
CTXR icon

Kestra Advisory Services’s Citius Pharmaceuticals CTXR Stock Holding History

Kestra Advisory Services’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,701
Closed -$46.3K – 2683
2024
Q3 		$46.3K Sell
3,701
-43
-1% -$724 ﹤0.01% 2503
2024
Q2 		$54.6K Buy
3,744
+508
+16% +$9.1K ﹤0.01% 2558
2024
Q1 		$72.6K Buy
3,236
+339
+12% +$6.19K ﹤0.01% 2384
2023
Q4 		$54.8K Sell
2,897
-769
-21% -$14.6K ﹤0.01% 2213
2023
Q3 		$62.7K Buy
3,666
+40
+1% +$951 ﹤0.01% 2045
2023
Q2 		$109K Sell
3,626
-51
-1% -$1.68K ﹤0.01% 1990
2023
Q1 		$108K Sell
3,677
-72
-2% -$2.08K ﹤0.01% 1948
2022
Q4 		$74K Buy
3,749
+222
+6% +$6.06K ﹤0.01% 2164
2022
Q3 		$107K Buy
3,527
+683
+24% +$18.8K ﹤0.01% 1976
2022
Q2 		$65K Buy
2,844
+1,239
+77% +$34K ﹤0.01% 2022
2022
Q1 		$72K Sell
1,605
-124
-7% -$4.9K ﹤0.01% 1946
2021
Q4 		$67K Buy
1,729
+91
+6% +$4.13K ﹤0.01% 1964
2021
Q3 		$83K Buy
+1,638
New +$82.2K ﹤0.01% 2068

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Kestra Advisory Services's CTXR Position: Q4 2024 in Review

Kestra Advisory Services sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 3,701 shares — an estimated $46.3K sold.

Kestra Advisory Services first reported a position in CTXR in Q3 2021 and held it in 13 quarters. The position peaked at $109K in Q2 2023. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • Kestra Advisory Services reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Kestra Advisory Services sold 3,701 Citius Pharmaceuticals shares in Q4 2024, an estimated $46.3K.
  • Kestra Advisory Services first reported a position in Citius Pharmaceuticals in Q3 2021 and held it in 13 quarters.
  • Kestra Advisory Services's Citius Pharmaceuticals position peaked at $109K in Q2 2023.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Kestra Advisory Services's 13F filing for Q4 2024, filed 10 Feb 2025.